Advice
Following a full submission.
Rasagiline (Azilect) is not recommended for use within NHS Scotland for the treatment of idiopathic Parkinson’s disease as monotherapy (without levodopa).
Rasagiline provides symptomatic improvement for patients with early Parkinson’s disease. However, there are no comparative data with the other monoamine-oxidase-B inhibitor, which is less expensive. The economic case has not been demonstrated.
Download detailed advice48KB (PDF)
Medicine details
- Medicine name:
- Rasagiline 1mg tablet (Azilect®)
- SMC ID:
- 243/06
- Indication:
- Idiopathic Parkinsons disease as monotherapy
- Pharmaceutical company
- Lundbeck Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 13 March 2006